Related Experiment Video
Updated: Apr 15, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Dabigatran for the prevention and treatment of thromboembolic disorders
Andres Enriquez1, Adrian Baranchuk, Damian Redfearn
1Division of Cardiology, Queen's University, Kingston, Ontario, Canada.
Insights
Dabigatran, a novel oral anticoagulant, offers superior stroke prevention in atrial fibrillation and comparable efficacy for venous thromboembolism compared to traditional therapies. It presents a favorable safety profile with reduced intracranial bleeding and no need for routine monitoring.
Area of Science:
- Pharmacology
- Cardiology
- Hematology
Background:
- Dabigatran is the first oral direct thrombin inhibitor in the non-vitamin K oral anticoagulants class.
- Established anticoagulants like warfarin and enoxaparin have limitations in efficacy and monitoring.
Purpose of the Study:
- To review the efficacy and safety of dabigatran compared to standard anticoagulants.
- To highlight dabigatran's advantages in clinical practice.
Main Methods:
- Review of clinical trial data comparing dabigatran with warfarin and enoxaparin.
- Analysis of safety profiles, focusing on bleeding events.
- Evaluation of pharmacokinetic properties and monitoring requirements.
Main Results:
- Dabigatran (150 mg twice daily) is superior to warfarin for stroke prevention in non-valvular atrial fibrillation.
- Dabigatran is non-inferior to enoxaparin for post-orthopedic surgery VTE prevention.
- Dabigatran is non-inferior to warfarin for VTE recurrence prevention.
- Dabigatran demonstrates a similar safety profile to standard anticoagulants, with a significant reduction in intracranial hemorrhage.
Conclusions:
- Dabigatran offers significant benefits for stroke prevention and venous thromboembolism.
- Its predictable pharmacokinetics allow fixed dosing without routine monitoring.
- Management of bleeding involves supportive measures, with hemostatic agents and a specific reversal agent (idarucizumab) under development.
Abstract:
Dabigatran, an oral direct thrombin inhibitor, was the first of a new class of drugs referred to as non-vitamin K oral anticoagulants. Dabigatran is better than warfarin for stroke prevention in non-valvular atrial fibrillation (dose of 150 mg twice a day), non-inferior to enoxaparin for venous thromboembolism prevention after orthopedic surgery and non-inferior to warfarin in preventing recurrence after acute venous thromboembolism. The safety profile is similar to standard anticoagulants, with significant reduction observed in intracranial hemorrhage. Other advantages include a rapid onset of action and a predictable pharmacokinetic profile, allowing a fixed-dose regimen without the need for routine anticoagulation monitoring. In the event of bleeding, general support measures are recommended and if severe, the use of non-specific hemostatic agents such as prothrombin complex concentrates and recombinant factor VIIa must be considered. A specific reversal agent (idarucizumab) is in development.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Pulmonary Embolism III: Nursing Management